Urvi Desai, MD
Neurology · Charlotte, NCNPI 1811948029
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by AstraZeneca at 49.0% of the total. Reporting peaked in 2019 at $95,023 and has fallen 73.9% since, to $24,776 in 2025. Among neurology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $682.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$128K
- Argenx US, Inc.$36K
- Sarepta Therapeutics, Inc.$26K
- CSL Behring$21K
- UCB, Inc.$11K
- Catalyst Pharmaceuticals, Inc.$9K
- plus $31K from 12 others
Across 163 payments — averaging $4259.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$201K
- Amgen$144K
- UCB SA$138K
- Takeda Pharmaceuticals U.S.A., Inc.$70K
- Tanabe Pharma America, Inc.$61K
- Alnylam Pharmaceuticals Inc.$28K
- plus $51K from 4 others
What the payments were for
- Consulting fees$71,41727%
- Speaking & faculty fees$127,42549%
- Travel & lodging$54,70621%
- Food & beverage$7,1363%
- Education$1,3821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 166 | $128,384 |
| Argenx US, Inc. | 38 | $36,195 |
| Sarepta Therapeutics, Inc. | 26 | $25,822 |
| CSL Behring | 52 | $20,958 |
| UCB, Inc. | 17 | $11,354 |
| Catalyst Pharmaceuticals, Inc. | 8 | $8,597 |
| Alnylam Pharmaceuticals Inc. | 17 | $8,361 |
| Amgen | 8 | $6,688 |
| ITF Therapeutics LLC | 11 | $4,552 |
| Akcea Therapeutics, Inc. | 8 | $3,823 |
| Biogen | 3 | $3,797 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,288 |
| UCB SA | 6 | $916 |
| PTC Therapeutics, Inc. | 18 | $168 |
| Johnson & Johnson | 1 | $99 |
| Tanabe Pharma America, Inc. | 1 | $43 |
| Novartis | 1 | $19 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$262,066 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AmvuttraVutrisiran Sodium | 24 | $2,914,812 |
| EvrysdiRisdiplam | 42 | $1,099,752 |
| FirdapseAmifampridine Phosphate | 23 | $840,867 |
| UltomirisRavulizumab-Cwvz | 17 | $782,256 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 51 | $665,381 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 56 | $613,226 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $178,782 |
| EmflazaDeflazacort | 11 | $103,323 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 35 | $20,480 |
| Pyridostigmine Bromide | 96 | $8,783 |
| Albuterol Sulfate | 35 | $5,207 |
| Mycophenolate Mofetil | 35 | $3,610 |
| Gabapentin | 94 | $1,441 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 65 | $1,105 |
| Azathioprine | 26 | $671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alnylam Pharmaceuticals Inc.Amvuttra | $8,361 | $2,914,81224 claims |
| Catalyst Pharmaceuticals, Inc.Firdapse | $8,597 | $840,86723 claims |
| AstraZenecaUltomiris | $128,384 | $782,25617 claims |
| CSL BehringHizentra | $20,958 | $665,38151 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $2,288 | $178,78213 claims |
| PTC Therapeutics, Inc.Emflaza | $168 | $103,32311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 566 neurology providers in North Carolina.
Other neurology in Charlotte
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Megan DonnellyCharlotte$601K
- Sanjay IyerCharlotte$581K
- Danielle Englert DoggettCharlotte$215K
- Robert WigginsCharlotte$138K
- Ardith CourtneyCharlotte$120K
- Joseph ChipmanCharlotte$118K
- Kurt WashburnCharlotte$66K
- Ziad HageCharlotte$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.